Singapore and Seoul top smart city government rankings
When it comes to city governments driving smart city development, Singapore and Seoul have emerged top in the rankings. That’s according to the Top 50 Smart City Government rankings released by Eden Strategy Institute.
The rankings further feature seven Chinese cities - Shanghai, Beijing, Chengdu, Shenzhen, Hangzhou, Guangzhou, and Chongqing – four of which (Chengdu, Chongqing, Guangzhou, and Hangzhou) are new entrants into the Top 50, signifying the rapid pace of urbanisation, technological growth, and smart city development within the country.
The Top 50 Smart City Government ranking (from 230 cities evaluated) focuses on the role of city governments in driving smart city development. The study aims to shed light on the importance of strategy, leadership, people-centricity, policies, ecosystem, incentives, and talent in determining the success and effectiveness of technologies deployed in smart cities, moving beyond evaluating the efficacy and outcomes of technological solutions applied by cities.
"Top smart city governments in the 2020/2021 rankings were able to collaborate and partner with public and private sector stakeholders; use digital solutions and data to deliver services and make decisions; all while considering implications on inclusion and citizen trust", says Calvin Chu Yee Ming, Managing Partner at Eden Strategy Institute.
One of the most distinct elements of Chinese governments' smart city strategies is the large focus on talent development, with city governments expending significant efforts to attract and retain top talent within their cities to drive smart city innovation and to increase technological competitiveness.
Singapore emerged top in the rankings alongside Seoul, London, Barcelona, and Helsinki; cities which were not only advanced in terms of technologies adopted throughout the city, but in their government's efforts to bring the city population along their digitalisation journey. Globally, eighteen new cities were welcomed into the Top 50 list, including cities such as Tallinn, Oslo, and Moscow.
Seo JungJin: Who is EY’s World Entrepreneur of 2021?
Seo JungJin, founder of biopharma firm Celltrion, which most recently developed an antibody treatment for COVID-19, has been named the EY World Entrepreneur of the Year 2021, becoming the first South Korean in the award’s 21-year history.
Regarded as one of the world’s most prestigious business awards program for entrepreneurs, the EY Entrepreneur of the Year celebrates visionary and innovative leaders from across 60 countries who are transforming the world and fostering growth.
JungJin, who is now honoroary chairman of Celltrion Group, was up against a worthy cast of entrepreneurial competitors, taking the crown from among 45 award winners across 38 countries and territories.
Speaking during the virtual event, JungJin described his own interpretation of entrepreneurship as something that brings together “a group of people toward a common vision, embracing challenges as opportunities and committing oneself to contribute to the greater good”.
Why was JungJin crowned King Entrepreneur?
A South Korean native and now 63 years of age, JungJin founded biopharmaceutical firm Celltrion in 2003. In the nearly two decades since its founding, Celltrion has lived up to its goal of advancing health and welfare for all by developing ground-breaking drugs to treat autoimmune disease, various forms of cancer and, most recently, COVID-19.
The company, which JungJin started with just US$45,000 and five of his colleagues, has since growth to more than 2,1000 employees with sales permits in more than 90 countries and revenues exceeding US$1.69bn.
According to the panel, JungJin’s story is a shining example of the power of an unstoppable entrepreneur to change the world with the pandel moved by both his incredible story and his purpose-driven leadership, innovative mindset and entrepreneurial spirit.
Described by the chair of the EY judging panel Rosaleen Blair as “representing everything an unstoppable should be” from taking on the world’s biggest health care challenges to consistently creating long-term value for his company, JungJin’s story is one of incredible tenacity and perseverance that the judging panel felt most represented the entrepreneurial spirit.
“He’s taken breathtaking risks, both personal and professional, to found Celltrion and grow it into one of the world’s leading biopharmaceutical companies,” says Stasia Mitchell, EY Global Entrepreneurship Leader. “His passion for creating affordable, life-saving health care and flair for tackling global problems has led to many treatments that have helped millions of people worldwide and was especially evident this past year through the creation of a COVID-19 antibody treatment.”
How did JungJin get there?
JungJin's entrepreneurial journey started at an early age when he worked as a taxi driver to get himself through Konkuk University in Seoul, South Korea. After studying industrial engineering, he rose through the ranks of Daewoo Motor Co. before losing his job amid the carmaker’s financial troubles following the 1997 Asian economic crisis.
Following this, JungJin started collaborating with colleagues to explore business opportunities in different industries, though none delivered lasting success. The turning point came after he attended a talk hosted by renowned scholars, which inspired him to focus on the biopharmaceutical sector.
And so he founded Celltrion with just US$45,000 of his savings. The launch of Remsima, credited with being the world's first antibody biosimilar, quickly moved Celltrion up the ranks of the country's fairly underdeveloped pharmaceutical sector. Celltrion followed this success with the launch of drugs for breast cancer and lymphoma that today are being used worldwide.
With ambitions to be the world’s first in different areas, Celltrion has pioneered numerous uncharted areas to great success over the past two decades, most recently responding to the global pandemic by successfully developing an antibody treatment for COVID-19 and working to ensure a timely supply of the safe and effective treatment.
“When I first started, my vision was to help patients gain access to safe, effective and affordable medicines and thereby enhance the quality of people’s lives,” explains JungJin. “The success of Celltrion has enabled me to expand on this while finding new ways to fuel my entrepreneurial drive.”